NSUN5 and RNA m⁵C epitranscriptomic regulation in tumor progression

Abstract

NSUN5 is a pivotal RNA 5-methylcytosine (m⁵C) methyltransferase that predominantly catalyzes site-specific m⁵C modifications in ribosomal RNA (rRNA), thereby regulating ribosome assembly, selective translation, and cellular stress adaptation. Recent studies have demonstrated that NSUN5 is aberrantly expressed in multiple cancer types, and its upregulation is often associated with advanced tumor stage, poor prognosis, and immune evasion. Mechanistically, NSUN5 modulates the m⁵C modification of rRNA or specific mRNAs, reshaping the cellular proteome and influencing tumor cell proliferation, migration, invasion, and stemness maintenance. Moreover, NSUN5 participates in tumor metabolic reprogramming, including glycolysis and lipid biosynthesis, as well as in cellular stress responses and resistance to chemotherapy and radiotherapy. NSUN5 can also mediate tumor microenvironmental regulation through RNA modifications, such as modulating macrophage polarization, enhancing antioxidative capacity, and facilitating immune escape. Functional crosstalk exists between NSUN5 and other RNA epigenetic regulators, forming a complex regulatory network. Given its central role and structural features, NSUN5 represents a potential therapeutic target and biomarker. Direct strategies include small-molecule inhibitors that block its methyltransferase activity, whereas indirect approaches focus on interfering with downstream signaling pathways or synergizing with other RNA modifications to inhibit tumor progression. Additionally, NSUN5 expression may serve as a stratification marker for patient classification and treatment response prediction, supporting precision oncology. Future research should focus on genome-wide target identification, integration of single-cell and spatial transcriptomics, and mechanism-driven drug development to advance the clinical translation of NSUN5-targeted interventions.

1 Introduction

With the rapid advancement of high-throughput sequencing technologies and chemical labeling approaches, RNA epitranscriptomics has emerged as a frontier in cancer biology research (Jiang et al., 2021). Unlike DNA and histone modifications, RNA modifications can dynamically regulate RNA splicing, stability, localization, and translation efficiency without altering the nucleotide sequence, thereby fine-tuning gene expression programs (Yuan et al., 2025). Accumulating evidence indicates that aberrant RNA modifications are prevalent across diverse tumor types and play critical roles in tumor initiation, progression, metabolic reprogramming, and therapeutic resistance (Wang et al., 2025).

To date, more than 170 chemical RNA modifications have been identified, among which m⁶A, m⁵C, and pseudouridine (Ψ) have been most extensively studied (Chen et al., 2024). Compared with m⁶A, research on RNA m⁵C modification in cancer has started relatively late but has gained increasing attention in recent years (Chen et al., 2025). m⁵C was first identified in tRNA and rRNA and was later confirmed to be widespread in mRNAs and various non-coding RNAs, participating in crucial biological processes such as RNA stability, nuclear export, and translation regulation (Li et al., 2025). The dynamic regulation of m⁵C depends on a sophisticated network of enzymes, mainly including “writers,” “readers,” and potentially “erasers (Li et al., 2025).” Known m⁵C writers predominantly consist of NSUN family proteins and DNMT2, both of which mediate site-specific m⁵C formation in an S-adenosylmethionine-dependent manner (Feng et al., 2023). Correspondingly, m⁵C readers specifically recognize this modification and mediate downstream functional outputs, whereas the existence of classical m⁵C erasers remains controversial, suggesting that m⁵C modifications are relatively stable yet finely regulated. Current studies indicate that the RNA m⁵C reader proteins mainly include YBX1, YBX2, ALYREF, and SRSF2, which specifically recognize m⁵C-modified RNAs and participate in the regulation of mRNA stability, nuclear export, and alternative splicing, thereby governing key post-transcriptional processes (Ma et al., 2023; Zhang et al., 2024a).

Members of the NSUN family, including NSUN1–7, play central roles in RNA m⁵C modification, exhibiting distinct substrate preferences, subcellular localization, and biological functions (Li et al., 2022). Among them, NSUN5, a relatively understudied m⁵C methyltransferase, has recently emerged as a key regulator in cancer biology (Sun et al., 2020). Unlike other NSUN family members, which predominantly target tRNAs or mRNAs, NSUN5 mainly mediates rRNA m⁵C modification and, by influencing ribosome function and selective translation, contributes to cellular stress adaptation and tumor progression (Sun et al., 2020). Growing evidence suggests that aberrant NSUN5 expression is closely associated with the development and prognosis of multiple tumor types (Zhou et al., 2023). In this review, we systematically summarize current knowledge regarding NSUN5 in cancer, highlighting its functional roles and underlying molecular mechanisms in tumor progression. Furthermore, we discuss potential strategies for targeting NSUN5 and the prospects for clinical translation, aiming to provide new insights and theoretical foundations for RNA modification-mediated cancer therapy (Figure 1).

FIGURE 1

2 Molecular characteristics and biological functions of NSUN5

2.1 Gene and protein structure of NSUN5

NSUN5 is a member of the NSUN family, encoding an S-adenosylmethionine (SAM)-dependent RNA methyltransferase (Zhou et al., 2023). In the human genome, the NSUN5 gene is located in a specific chromosomal region, and its sequence is highly conserved across eukaryotes, with homologs detectable from yeast to mammals, suggesting that NSUN5 performs fundamental and evolutionarily conserved biological functions (Ding et al., 2022). This high degree of evolutionary conservation supports its critical role in maintaining ribosome function and cellular homeostasis. At the protein structural level, NSUN5 is a canonical RNA m⁵C methyltransferase, with a core domain that adopts a highly conserved Rossmann-like fold. This domain facilitates binding to the methyl donor SAM and catalyzes the methylation reaction, a feature shared by all NSUN family members and essential for their function as m⁵C “writers (Liu et al., 2022).” Compared with other NSUN proteins, NSUN5 exhibits a relatively compact structure and lacks prominent auxiliary RNA-binding domains, which likely underlies its substrate preference for rRNA. The catalytic activity of NSUN5 depends on several highly conserved amino acid residues, particularly a cysteine residue located in the catalytic center, which is indispensable for m⁵C formation (Xu et al., 2025). This cysteine forms a covalent intermediate with the cytosine in the RNA substrate, ensuring precise methyl transfer. In addition, NSUN5 contains conserved motifs involved in SAM binding and substrate positioning, collectively guaranteeing the specificity and efficiency of its methyltransferase activity (Chen et al., 2019). Notably, these structural features not only define NSUN5 enzymatic function but also provide a theoretical basis for drug targeting. The well-defined SAM-binding pocket and catalytic core render NSUN5 amenable to inhibition by small-molecule compounds, an aspect of practical significance for subsequent discussions on therapeutic strategies (Chen et al., 2019).

2.2 Characteristics of NSUN5-Mediated RNA m⁵C modification

As a key RNA m⁵C writer, NSUN5 exhibits distinct substrate specificity and site selectivity compared with other NSUN family members (Chen et al., 2019). Current evidence indicates that NSUN5 primarily targets ribosomal RNA (rRNA), especially highly conserved sites within the large subunit rRNA (Chen et al., 2019). These modification sites are evolutionarily conserved across species, underscoring the fundamental role of NSUN5-mediated rRNA m⁵C in ribosome structural stability and translational function (Chen et al., 2019).

Beyond rRNA, emerging evidence suggests that NSUN5 may also contribute to mRNA m⁵C modification. High-throughput sequencing data indicate that NSUN5 can methylate specific mRNAs under certain cellular conditions or stress states, potentially influencing mRNA stability, translation efficiency, or subcellular localization (Zha et al., 2024). Although the exact repertoire and distribution of NSUN5-modified mRNAs remain to be systematically validated, these observations provide a mechanistic basis for subsequent findings in which NSUN5-mediated mRNA modifications affect cellular responses and tumor-related translation programs. Compared with NSUN2, which primarily targets tRNA and mRNA, NSUN5 appears to regulate the global translation program indirectly through ribosome modification rather than directly controlling individual transcript fate. In terms of site specificity, NSUN5-catalyzed m⁵C modifications typically occur at structurally conserved cytosine residues located in functionally critical regions of rRNA, such as the ribosomal subunit assembly sites and peptidyl transfer center (Zha et al., 2024). This selective modification allows NSUN5 to fine-tune ribosome performance and indirectly influence the translational efficiency of specific mRNAs, thereby enabling “translation reprogramming.” Functionally, NSUN5 differs from other m⁵C writers: NSUN2 primarily acts on tRNA and mRNA, regulating RNA stability, nuclear export, and cell proliferation, while DNMT2, though possessing methyltransferase activity, has a limited substrate range, mainly modifying specific tRNAs (Zha et al., 2024). In contrast, NSUN5 preferentially impacts overall ribosome function through rRNA modification, providing a unique advantage in stress adaptation and tumor-associated translational regulation (Zha et al., 2024).

2.3 Physiological functions of NSUN5

NSUN5 functions as a S-adenosylmethionine (SAM)-dependent RNA methyltransferase, catalyzing the site-specific methylation of cytosine residues in rRNA to form 5-methylcytosine (Heissenberger et al., 2019). This enzymatic activity is critical for ribosome biogenesis and functional fidelity, as NSUN5-mediated methylation occurs at structurally conserved sites within the large subunit rRNA that are essential for ribosomal assembly and the peptidyl transferase reaction (Jiang et al., 2020a). By stabilizing rRNA structure and optimizing ribosome conformation, NSUN5 indirectly regulates the efficiency and accuracy of global protein translation, which is particularly important under cellular stress conditions (Jiang et al., 2020a). Beyond ribosomal RNA, emerging evidence suggests that NSUN5 may also catalyze m⁵C modification on selected mRNAs, thereby modulating mRNA stability, translational efficiency, or subcellular localization in a context-dependent manner (Hu et al., 2025). Through these dual activities on rRNA and mRNA, NSUN5 contributes to cellular stress adaptation, proliferation control, and tumor-associated translational reprogramming, highlighting its central role in maintaining cellular homeostasis and regulating gene expression at the post-transcriptional level (Hu et al., 2025). Under physiological conditions, NSUN5 is expressed across multiple tissues and cell types, generally at stable levels, consistent with its role in fundamental cellular processes (Zhang et al., 2024b). Unlike certain NSUN family members that exhibit tissue-specific high expression, NSUN5 expression primarily maintains basal translational activity and cellular homeostasis rather than driving specialized differentiation programs. This ribosome-centric regulatory mode also provides a foundation for understanding the pathological roles of NSUN5, particularly in tumor progression.

3 Molecular mechanisms of NSUN5 in cancer progression

In Table 1, we summarizes the multifaceted roles of NSUN5 in cancer biology, highlighting its involvement in tumor metabolism, stress adaptation, proliferation, and progression.

3.1 NSUN5-mediated tumor metabolism and stress adaptation

Accumulating evidence indicates that NSUN5 plays a critical role in tumor metabolic reprogramming, particularly by promoting glycolysis. In clear cell renal cell carcinoma (ccRCC), NSUN5 is significantly upregulated and enhances glucose uptake, lactate production, and extracellular acidification, thereby reinforcing the classic Warburg effect and supporting rapid tumor cell proliferation (Wang et al., 2023). Mechanistically, NSUN5 mediates m⁵C modification of target metabolic enzyme mRNAs, increasing their stability and protein expression, with ENO3 identified as a key downstream effector. Disruption of the NSUN5–ENO3 axis markedly reduces glycolytic activity and cell proliferation, highlighting NSUN5 as a crucial link between RNA epigenetic modification and metabolic reprogramming in cancer (Wang et al., 2023). Recent studies also show that CDK13 can phosphorylate NSUN5 at Ser327, enhancing its m⁵C methyltransferase activity. This, in turn, stabilizes ACC1 mRNA and promotes its nuclear export, facilitating fatty acid synthesis and accumulation in prostate cancer cells (Zhang et al., 2023). The CDK13–NSUN5–ACC1 axis thus reveals a novel mechanism by which NSUN5 connects RNA modification to lipid metabolic reprogramming and identifies a potential therapeutic target in prostate cancer (Zhang et al., 2023). In hepatocellular carcinoma (HCC), NSUN5 is highly expressed and stabilizes EFNA3 mRNA via m⁵C modification, promoting cell proliferation and glycolysis. EFNA3 overexpression can rescue the inhibitory effects induced by NSUN5 depletion, underscoring the functional importance of the NSUN5/EFNA3 axis in HCC progression (Han et al., 2025a). Interestingly, in gliomas, NSUN5 is silenced via DNA methylation (Figure 2). Its loss leads to demethylation at 28S rRNA C3782, globally reducing protein synthesis while activating adaptive translational programs that support cell survival under stress, suggesting a tumor-suppressive role of NSUN5 in this context, closely associated with prolonged patient survival (Yin et al., 2025).

FIGURE 2

3.2 Regulation of tumor cell proliferation and survival by NSUN5

NSUN5 promotes tumor cell proliferation and exerts oncogenic effects in multiple cancers (Figure 2). In HCC, elevated NSUN5 expression correlates with poor prognosis and enhances target mRNA stability via m⁵C modification, thereby activating pro-proliferative signaling pathways. Specifically, NSUN5 stabilizes ZBED3 mRNA, activating the Wnt/β-catenin signaling axis to promote tumor growth, demonstrating a critical link between RNA modification and canonical oncogenic signaling (Gu et al., 2024). In ccRCC, NSUN5 is markedly upregulated, with high expression associated with age, tumor size, TNM stage, and poor prognosis. Functional studies show that NSUN5 suppresses tumor cell senescence while promoting proliferation and migration, suggesting its potential as both a diagnostic/prognostic biomarker and a therapeutic target (Huang et al., 2024). In colorectal cancer (CRC), NSUN5 overexpression correlates with advanced tumor stage and drives cell proliferation through regulation of cell cycle proteins (e.g., CDK4, CDK6, CCNE1) and the Rb pathway (Jiang et al., 2020b). In glioblastoma (GBM), NSUN5 is overexpressed and associated with poor patient survival (Zhou et al., 2023). Mechanistically, NSUN5-mediated m⁵C modification of 28S rRNA enhances protein synthesis, promoting proliferation, sphere formation, migration, temozolomide resistance, and maintenance of tumor stemness (Zhou et al., 2023). Similarly, in esophageal and other gastrointestinal cancers, NSUN5 stabilizes METTL1 mRNA via m⁵C, accelerating proliferation and cell cycle progression (Cui et al., 2025). In cholangiocarcinoma (CCA), NSUN5 enhances GLS mRNA stability through m⁵C modification at the 137C site, promoting proliferation, migration, invasion, and resistance to cuproptosis (Shu et al., 2025). In prostate cancer (PCa), NSUN5 promotes tumor growth, migration, and immune-suppressive microenvironment formation via PI3K-AKT pathway activation and macrophage polarization (Huang et al., 2025).

3.3 NSUN5-driven tumor cell migration and invasion

In HCC, NSUN5 is highly expressed and recruits WDR5 to enrich H3K4me3 at the SMAD3 promoter, facilitating SMAD3-mediated epithelial–mesenchymal transition (EMT) and enhancing tumor cell migration and invasion, highlighting its role in metastasis (Han et al., 2025b). Additionally, NSUN5 (also referred to as NOP2) mediates m⁵C modification of XPD mRNA, increasing its stability and consequently suppressing proliferation, migration, and invasion, suggesting the NSUN5/NOP2–XPD axis as a potential therapeutic target. In CCA, NSUN5-mediated m⁵C modification of GLS mRNA at the 137C site stabilizes GLS protein, promoting migration, invasion, and resistance to cuproptosis, further underscoring its role in tumor progression and metabolic regulation (Sun and Ding, 2023).

3.4 NSUN5 in chemotherapy and radiotherapy resistance

NSUN5 overexpression contributes to chemoresistance in CRC by upregulating BRCA2 and BRIP1 and interacting with them to inhibit DNA damage-induced cell death, suggesting NSUN5 as a regulator of chemoresistance and a potential therapeutic target (Xu et al., 2025). In ccRCC, NSUN5 activates p53 signaling to suppress proliferation, migration, and invasion while promoting apoptosis, affecting drug sensitivity and highlighting its relevance as a therapeutic intervention point. NSUN5 also binds SLC7A11 mRNA, enhancing its translation and increasing resistance to ferroptosis, which is critical in acute-on-chronic liver failure (ACLF) models and regulates RNA m⁵C levels (Li et al., 2023).

3.5 NSUN5 in the tumor microenvironment and immune regulation

NSUN5 maintains redox homeostasis by mediating m⁵C modification of GPX4 mRNA and activates the cGAS-STING pathway, enhancing anti-tumor immune responses in colorectal adenocarcinoma (Chen et al., 2023). In gliomas, NSUN5 catalyzes m⁵C modification of CTNNB1 caRNA, recruiting TET2 to oxidize it to 5hmC. RBFOX2 recognition of 5hmC-caRNA facilitates its degradation, suppressing β-catenin expression and enhancing tumor-associated macrophage (TAM) phagocytic activity, revealing the NSUN5/TET2/RBFOX2 axis as a key mechanism linking RNA metabolism to immune regulation (Wu et al., 2024). In gastric cancer, NSUN5 overexpression correlates with tumor stage and poor prognosis, promoting proliferation, stemness, and migration via WNT/β-catenin activation while inhibiting CD8⁺ T cell infiltration, contributing to immune evasion. In PCa, NSUN5 promotes tumor progression by activating PI3K-AKT signaling and inducing pro-tumor macrophage polarization, establishing an immunosuppressive microenvironment (Liu et al., 2024).

3.6 Crosstalk between NSUN5-Mediated m⁵C and other epigenetic modifications

In COAD, NSUN5-mediated m⁵C of GPX4 mRNA synergizes with m⁶A modifications mediated by RBM15B and IGFBP2, collectively maintaining redox homeostasis and activating cGAS–STING signaling, highlighting functional crosstalk between RNA modifications in anti-tumor immunity (Chen et al., 2023). In esophageal cancer (ESCA), NSUN5 directly binds METTL1 transcripts and catalyzes m⁵C modification, positively regulating METTL1 expression, promoting proliferation and cell cycle progression, and reversing the tumor-suppressive effect of NSUN5 depletion (Cui et al., 2025). In gliomas, NSUN5-mediated m⁵C modification of CTNNB1 caRNA recruits TET2 for oxidation to 5hmC and RBFOX2 for degradation, downregulating β-catenin and enhancing TAM phagocytosis, demonstrating NSUN5/TET2/RBFOX2-mediated RNA crosstalk in immune microenvironment regulation (Wu et al., 2024). Furthermore, in gliomas, NSUN5 is regulated by DNA methylation; its loss shifts cytoplasmic DNA sensing from cGAS–STING-dependent to DNA-PK–HSPA8-dependent STING-independent pathways, delaying but enhancing type I interferon responses and promoting M1 polarization and chemotaxis of microglia (Wu et al., 2024). These findings reveal context-dependent tumor-suppressive activity in vitro yet poor clinical prognosis, highlighting the complex role of NSUN5 in tumor immune regulation.

4 Therapeutic strategies targeting NSUN5 and translational prospects

Therapeutic strategies targeting NSUN5 can be broadly classified into direct inhibition of its enzymatic activity and indirect modulation of related signaling pathways, while NSUN5 also holds potential as a biomarker. Direct targeting primarily relies on small-molecule inhibitors that competitively or covalently bind to NSUN5, blocking its methyltransferase activity and thereby suppressing m⁵C modification of RNA (Janin et al., 2019). The crystal structure of NSUN5 reveals potential drug-binding pockets, facilitating rational inhibitor design. However, developing specific inhibitors faces several challenges, including the highly conserved nature of the catalytic pocket, limited selectivity of potential compounds, and uncertain pharmacokinetic properties in vivo (Heissenberger et al., 2019). Future drug development may benefit from integrating structural biology, computational drug design, and high-throughput screening to improve both target specificity and bioactivity of candidate compounds.

Indirect targeting of NSUN5-related pathways is another feasible approach. NSUN5 modulates RNA stability and translational efficiency, thereby affecting downstream signaling axes such as mTOR and ISR, which in turn regulate tumor cell proliferation and stress adaptation. Thus, combined inhibition of these translational regulatory pathways could enhance anti-tumor efficacy (Schosserer et al., 2015). Moreover, the functional interplay between NSUN5 and other RNA modification factors (e.g., NSUN2, DNMT2) in tumors provides additional opportunities for multi-targeted intervention, enabling layered regulation of RNA epigenetic programs to improve therapeutic outcomes. Finally, NSUN5 has promising applications as a biomarker. Its expression levels and enzymatic activity can stratify patients, identifying tumor subtypes dependent on NSUN5 activity and guiding clinical treatment decisions (Tian et al., 2025). NSUN5 may also predict responses to chemotherapy, targeted therapy, or immunotherapy, facilitating personalized precision medicine. With deeper understanding of NSUN5 biology and mechanisms, its translational potential in cancer diagnosis and therapy is substantial, serving both as a therapeutic target and as a predictive biomarker for patient stratification and treatment response.

5 Discussion

Emerging evidence indicates that NSUN5 exhibits context-dependent functions across different cancer types. In hepatocellular carcinoma, colorectal cancer, and clear cell renal cell carcinoma, NSUN5 is frequently overexpressed, promoting tumor cell proliferation, migration, invasion, and metabolic reprogramming. Conversely, in gliomas, NSUN5 is often silenced, leading to decreased 28S rRNA m⁵C methylation and reduced global protein synthesis, which paradoxically suppresses tumor growth while activating adaptive translational programs under stress (Hu et al., 2025). The dual roles of NSUN5 may stem from tumor-type-specific differences in cellular context, metabolic demands, and microenvironmental stress, as well as the distinct repertoire of target RNAs and downstream signaling pathways. These findings suggest that NSUN5 functions as either an oncogene or tumor suppressor depending on the cellular and molecular landscape, emphasizing the importance of context-specific investigation when considering NSUN5-targeted interventions (Guarnacci et al., 2024).

The mechanisms driving NSUN5 overexpression vary among cancers. In some tumors, DNA hypomethylation at the NSUN5 promoter or enhancers may lead to transcriptional activation, whereas in others, histone modifications such as H3K4me3 or H3K27ac enrichment contribute to elevated expression. Furthermore, functional crosstalk with other RNA modification pathways, including m⁶A, may indirectly influence NSUN5 transcription or activity, forming complex epitranscriptomic regulatory networks (Guarnacci et al., 2024). These observations highlight that NSUN5 dysregulation in cancer is multifactorial, involving both epigenetic and post-transcriptional mechanisms, which may differ depending on tumor type, stage, and cellular stress conditions.

Current studies on NSUN5 in tumor immunity are still in their infancy. Preliminary data suggest that NSUN5 can modulate oxidative stress responses, macrophage polarization, and cGAS–STING signaling, yet it remains unclear whether NSUN5 directly influences immune checkpoint molecules such as PD-L1 or affects the efficacy of immunotherapies. Considering the critical role of RNA modifications in shaping the tumor immune microenvironment, further investigation is warranted to elucidate whether NSUN5 contributes to immune evasion and can be leveraged to enhance immunotherapy response. While most studies have focused on NSUN5-mediated rRNA m⁵C modification, its potential regulatory effects on noncoding RNAs (ncRNAs), including lncRNAs, circRNAs, and chromatin-associated RNAs (caRNAs), remain largely unexplored (Dominissini and Rechavi, 2017). These RNAs are known to influence transcription, epigenetic state, and RNA stability, suggesting that NSUN5 may exert broader effects on gene expression and chromatin dynamics. Investigating NSUN5-mediated m⁵C modifications on ncRNAs and caRNAs could provide novel insights into its role in tumor biology and reveal additional therapeutic opportunities (Dominissini and Rechavi, 2017). Overall, the context-specific functions, diverse regulatory mechanisms, and largely unexplored roles of NSUN5 in tumor immunity and noncoding RNA regulation underscore the complexity of its contribution to cancer biology. Addressing these gaps will not only advance our understanding of NSUN5 biology but also inform the rational design of NSUN5-targeted therapies and predictive biomarkers.

6 Conclusion and future perspectives

In summary, NSUN5, as an RNA m⁵C methyltransferase, plays a central role in the initiation and progression of multiple cancers. By regulating RNA stability, translation efficiency, and downstream signaling pathways, NSUN5 promotes tumor cell proliferation, migration, invasion, and stemness, while also participating in metabolic reprogramming, stress adaptation, chemoresistance, and modulation of the tumor immune microenvironment. Numerous studies indicate that NSUN5 overexpression correlates with advanced tumor stage, poor prognosis, and immune evasion, highlighting its oncogenic role and potential as both a therapeutic target and biomarker for patient stratification and treatment response. Despite these advances, current research on NSUN5 has several limitations. First, reported RNA targets and signaling pathways are not yet systematically characterized, and high-resolution, genome-wide mapping of NSUN5 targets and modification sites remains lacking. Second, most studies rely on cell lines or mouse models, with limited integration of patient-derived single-cell or spatial transcriptomic data, hindering comprehensive understanding of NSUN5 role in tumor heterogeneity and the microenvironment. Finally, while potential NSUN5 inhibitors have been proposed, systematic studies bridging mechanistic insights, drug development, and clinical translation are still limited.

Future research should focus on several directions: (i) leveraging high-throughput sequencing, single-cell, and spatial transcriptomics to accurately identify NSUN5 RNA targets and define their roles across tumor subtypes; (ii) elucidating dynamic regulatory mechanisms of NSUN5 in tumor immunity, metabolism, and stress adaptation; and (iii) integrating mechanistic studies with drug development to advance small-molecule inhibitors or combinatorial therapeutic strategies, providing viable clinical avenues for NSUN5-targeted intervention. These efforts are expected to comprehensively reveal the role of NSUN5 in tumor biology and facilitate its translational application in cancer diagnosis and therapy.

References

• 1

  Chen P. Zhang T. Yuan Z. Shen B. Chen L. (2019). Expression of the RNA methyltransferase Nsun5 is essential for developing cerebral cortex. Mol. Brain12, 74. 10.1186/s13041-019-0496-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2

  Chen B. Hong Y. Zhai X. Deng Y. Hu H. Tian S. et al (2023). m6A and m5C modification of GPX4 facilitates anticancer immunity via STING activation. Cell Death & Disease14, 809. 10.1038/s41419-023-06241-w

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3

  Chen X. Yuan Y. Zhou F. Li L. Pu J. Jiang X. (2024). RNA modification in normal hematopoiesis and hematologic malignancies. MedComm5, e787. 10.1002/mco2.787

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4

  Chen X. Yuan Y. Zhou F. Huang X. Li L. Pu J. et al (2025). RNA m5C modification: from physiology to pathology and its biological significance. Front. Immunology16, 1599305. 10.3389/fimmu.2025.1599305

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5

  Cui Y. Hu Z. Zhang C. (2025). RNA methyltransferase NSUN5 promotes esophageal cancer via 5-Methylcytosine modification of METTL1. Mol. Carcinogenesis64, 399–409. 10.1002/mc.23857

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6

  Ding C. Lu J. Li J. Hu X. Liu Z. Su H. et al (2022). RNA-methyltransferase Nsun5 controls the maternal-to-zygotic transition by regulating maternal mRNA stability. Clin. Translational Medicine12, e1137. 10.1002/ctm2.1137

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7

  Dominissini D. Rechavi G. (2017). 5-methylcytosine mediates nuclear export of mRNA. Cell Research27, 717–719. 10.1038/cr.2017.73

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8

  Feng J. Xu T. He M. Li J. Yao P. Ma C. et al (2023). NSUN2-mediated m5C modification of HBV RNA positively regulates HBV replication. PLoS Pathogens19, e1011808. 10.1371/journal.ppat.1011808

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9

  Gu X. Li P. Gao X. Ru Y. Xue C. Zhang S. et al (2024). RNA 5-methylcytosine writer NSUN5 promotes hepatocellular carcinoma cell proliferation via a ZBED3-dependent mechanism. Oncogene43, 624–635. 10.1038/s41388-023-02931-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10

  Guarnacci M. Zhang P. H. Kanchi M. Hung Y. T. Lin H. Shirokikh N. E. et al (2024). Substrate diversity of NSUN enzymes and links of 5-methylcytosine to mRNA translation and turnover. Life Science Alliance7, e202402613. 10.26508/lsa.202402613

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11

  Han Y. Deng X. Chen H. Chen J. Xu W. Liu L. (2025a). NSUN5 accelerates the progression of liver hepatocellular carcinoma by m5C-EFNA3-mediated glycolysis. BMC Cancer25, 1237. 10.1186/s12885-025-14714-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12

  Han H. Zhang C. Shi W. Wang J. Zhao W. Du Y. et al (2025b). NSUN5 facilitates hepatocellular carcinoma progression by increasing SMAD3 expression. Adv. Science Weinheim, Baden-Wurttemberg, Ger.12, e2404083. 10.1002/advs.202404083

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13

  Heissenberger C. Liendl L. Nagelreiter F. Gonskikh Y. Yang G. Stelzer E. M. et al (2019). Loss of the ribosomal RNA methyltransferase NSUN5 impairs global protein synthesis and normal growth. Nucleic Acids Research47, 11807–11825. 10.1093/nar/gkz1043

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14

  Hu X. Ding C. Lu J. Li J. Ren X. Xia W. et al (2025). RNA-m5C regulatory atlas of human fetal tissues uncover the activities of Nsun2/Jarid2/Alyref axis. J. Advanced Research. S2090-1232 (25), 00595–00598. 10.1016/j.jare.2025.08.004

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15

  Huang C. Luo M. Y. Wen N. Q. Chen Y. M. Zhang L. Z. Cao Y. (2024). The prognostic implications and oncogenic role of NSUN5 in clear cell renal cell carcinoma. Clin. Experimental Medicine25, 8. 10.1007/s10238-024-01507-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16

  Huang M. Zou H. Liang Y. Cao F. Teng Q. Guan Y. et al (2025). Nop2/Sun domain family member 5 contributes to tumorigenic properties in prostate cancer by engaging the PI3K-AKT pathway and tumor-associated macrophages. Biochimica Biophysica Acta. Mol. Basis Dis.1871, 167974. 10.1016/j.bbadis.2025.167974

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17

  Janin M. Ortiz-Barahona V. de Moura M. C. Martínez-Cardús A. Llinàs-Arias P. Soler M. et al (2019). Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathol.138, 1053–1074. 10.1007/s00401-019-02062-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18

  Jiang Z. Li S. Han M. J. Hu G. M. Cheng P. (2020a). Erratum: high expression of NSUN5 promotes cell proliferation via cell cycle regulation in colorectal cancer. Am. Journal Translational Research12, 6976.

  • Pubmed Abstract
  • Google Scholar

• 19

  Jiang Z. Li S. Han M. J. Hu G. M. Cheng P. (2020b). High expression of NSUN5 promotes cell proliferation via cell cycle regulation in colorectal cancer. Am. Journal Translational Research12, 3858–3870.

  • Pubmed Abstract
  • Google Scholar

• 20

  Jiang X. Liu B. Nie Z. Duan L. Xiong Q. Jin Z. et al (2021). The role of m6A modification in the biological functions and diseases. Signal Transduction Targeted Therapy6, 74. 10.1038/s41392-020-00450-x

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21

  Li L. Li M. Zheng J. Li Z. Chen X. (2023). Knocking down NSUN5 inhibits the development of clear cell renal cell carcinoma by inhibiting the p53 pathway. Aging15, 4757–4773. 10.18632/aging.204761

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22

  Li M. Tao Z. Zhao Y. Li L. Zheng J. Li Z. et al (2022). 5-methylcytosine RNA methyltransferases and their potential roles in cancer. J. Translational Medicine20, 214. 10.1186/s12967-022-03427-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23

  Li C. Yuan Y. Jiang X. Wang Q. (2025). Roles and mechanisms of NSUN2-mediated RNA m(5)C modification in cancer progression and immune modulation. Front. Immunology16, 1702436. 10.3389/fimmu.2025.1702436

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24

  Liu J. Ren Z. Yang L. Zhu L. Li Y. Bie C. et al (2022). The NSUN5-FTH1/FTL pathway mediates ferroptosis in bone marrow-derived mesenchymal stem cells. Cell Death Discovery8, 99. 10.1038/s41420-022-00902-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25

  Liu S. Liu Y. Zhou Y. Xia G. Liu H. Zeng Y. et al (2024). NSUN5 promotes tumorigenic phenotypes through the WNT signaling pathway and immunosuppression of CD8+ T cells in gastric cancer. Cell. Signalling124, 111475. 10.1016/j.cellsig.2024.111475

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26

  Ma H. L. Bizet M. Soares Da Costa C. Murisier F. de Bony E. J. Wang M. K. et al (2023). SRSF2 plays an unexpected role as reader of m(5)C on mRNA, linking epitranscriptomics to cancer. Mol. Cell83, 4239–4254.e10. 10.1016/j.molcel.2023.11.003

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27

  Schosserer M. Minois N. Angerer T. B. Amring M. Dellago H. Harreither E. et al (2015). Methylation of ribosomal RNA by NSUN5 is a conserved mechanism modulating organismal lifespan. Nat. Communications6, 6158. 10.1038/ncomms7158

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28

  Shu M. Guo K. Huang Y. Wang W. (2025). NSUN5 promotes cholangiocarcinoma progression by enhancing GLS mRNA stabilization. J. Cancer Research Clinical Oncology151, 117. 10.1007/s00432-025-06163-4

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29

  Sun G. F. Ding H. (2023). NOP2-mediated m5C methylation of XPD is associated with hepatocellular carcinoma progression. Neoplasma70, 340–349. 10.4149/neo_2023_230110N17

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 30

  Sun B. Zeng H. Liang J. Zhang L. Hu H. Wang Q. et al (2020). “NSUN5 facilitates viral RNA recognition by RIG-I receptor. ”J. Immunology. 205. Baltimore, Md, 3408–3418. 10.4049/jimmunol.1901455

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 31

  Tian L. Song W. Wu J. Lan Y. Chen L. (2025). Diagnostic and predictive values of m5C-associated genes in idiopathic pulmonary fibrosis. Mol. Medicine Reports31, 53. 10.3892/mmr.2024.13418

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 32

  Wang J. Ju H. J. Zhang F. Tian H. Wang W. G. Ma Y. L. et al (2023). A novel NSUN5/ENO3 pathway promotes the Warburg effect and cell growth in clear cell renal cell carcinoma by 5-methylcytosine-stabilized ENO3 mRNA. Am. Journal Translational Research15, 878–895.

  • Pubmed Abstract
  • Google Scholar

• 33

  Wang Q. Yuan Y. Zhou Q. Jia Y. Liu J. Xiao G. et al (2025). RNA N4-acetylcytidine modification and its role in health and diseases. MedComm6, e70015. 10.1002/mco2.70015

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 34

  Wu R. Sun C. Chen X. Yang R. Luan Y. Zhao X. et al (2024). NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion. Proc. Natl. Acad. Sci. U. S. A. 121, e2321611121. 10.1073/pnas.2321611121

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 35

  Xu Y. Qin C. Zhang M. Wu Q. Li Z. Mo H. et al (2025). NSUN5 mediates resistance to doxorubicin via Up-regulation of DNA damage repair proteins BRCA2 and BRIP1 in colorectal cancer. Am. Journal Pathology195, 1921–1935. 10.1016/j.ajpath.2025.06.013

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 36

  Yin A. A. Yao Y. Liu Y. F. Ji Y. S. He Y. L. Ma T. C. et al (2025). DNA methylation variations of DNA damage response in glioblastoma: NSUN5 modulates tumor-intrinsic cytosolic DNA-sensing and microglial behavior. J. Translational Medicine23, 907. 10.1186/s12967-025-06360-2

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 37

  Yuan Y. Zhang D. Wang J. Tang L. Duan Y. Duan L. et al (2025). N4-acetylcytidine modification of LINC02802 promotes non-small cell lung cancer progression by modulating mitochondrial NAD+/NADH ratio. Int. Journal Biological Sciences21, 4908–4926. 10.7150/ijbs.116639

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 38

  Zhang H. Li H. Yao J. Zhao M. Zhang C. (2024). The mutation of NSUN5 R295C promotes preeclampsia by impairing decidualization through downregulating IL-11Rα. iScience27, 108899. 10.1016/j.isci.2024.108899

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 39

  Zhang Y. Chen X. N. Zhang H. Wen J. K. Gao H. T. Shi B. et al (2023). CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. Cell Death Differentiation30, 2462–2476. 10.1038/s41418-023-01223-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 40

  Zhang X. An K. Ge X. Sun Y. Wei J. Ren W. et al (2024a). NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m(5)C methylation. Breast Cancer Research BCR26, 94. 10.1186/s13058-024-01847-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 41

  Zhang H. Li X. Bai J. Zhang C. (2024b). Mice with NOP2/sun RNA methyltransferase 5 deficiency die before reaching puberty due to fatal kidney damage. Ren. Failure46, 2349139. 10.1080/0886022X.2024.2349139

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 42

  Zhou J. Kong Y. S. Vincent K. M. Dieters-Castator D. Bukhari A. B. Glubrecht D. et al (2023). RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma. Mol. Oncology17, 1763–1783. 10.1002/1878-0261.13434

  • Pubmed Abstract
  • CrossRef
  • Google Scholar